Guggenheim Assumes Xenon Pharmaceuticals at Buy, Announces Price Target of $73

Guggenheim analyst Delma Caiati has initiated coverage of Xenon Pharmaceuticals (NASDAQ: XENE) with a Buy rating. The firm has set a price target of $73 for the stock.